UPMC-Mercy Hospital

Pittsburgh, Pennsylvania 15243

12 studies enrolling now · 43 studies all time

What they study most

ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Acute Ischemic Stroke, Acute Pain, Acute Pain Due to Trauma, Adult-Acquired Buried Penis, Advanced Lung Non-Small Cell Carcinoma, Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8

Studies at this site

• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) — Recruiting now
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma — Recruiting now
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease — Recruiting now
• Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers — Recruiting now
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) — Recruiting now
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer — Recruiting now
• Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention — Recruiting now
• StrokeNet Thrombectomy Endovascular Platform — Recruiting now
• Personalized Postoperative Pain Management Following Thoracic Surgery in Adults — Recruiting now
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) — Running, not enrolling
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — Running, not enrolling
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair — Running, not enrolling
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer — Running, not enrolling
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers — Running, not enrolling
• Silver Nitrate vs. Triamcinolone for Treatment of Hypergranulation Tissue — Withdrawn before enrolling
• Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease — Starting soon
• CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy — Running, not enrolling
• Prediction and Prevention of Postoperative Mortality and Morbidity — Starting soon
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial — Running, not enrolling
• Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker — Running, not enrolling
• Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) — Running, not enrolling
• Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases — Running, not enrolling
• Autologous Fat Grafting Beneath Penile Split Thickness Skin Graft Placement During Penile Reconstruction — Starting soon
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer — Stopped early
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study — Running, not enrolling
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer — Running, not enrolling
• Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer — Running, not enrolling
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) — Running, not enrolling
• Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation — Running, not enrolling
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) — Completed
• Multi-arm Optimization of Stroke Thrombolysis — Completed
• Emergency Department-Initiated Buprenorphine Validation Network Trial — Completed
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer — Withdrawn before enrolling
• Superficial Partial-Thickness Burn Study — Stopped early
• Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest — Stopped early
• Established Status Epilepticus Treatment Trial — Completed
• Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care — Stopped early
• Amantadine to Speed Awakening After Cardiac Arrest — Completed
• The Mobile PTSD Coach App in Acute Injury Survivors — Completed
• The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID) — Completed
• Antihypertensive Treatment of Acute Cerebral Hemorrhage-II — Stopped early
• Red Cell Storage Duration Study — Completed
• Text-message Program to Reduce Risky Sexual Behavior in Young Adult Female Emergency Department (ED) Patients — Completed